Trials
Search / Trial NCT05650281

Silent Progression Activity Monitoring - SPAM Study

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Dec 5, 2022

Trial Information

Current as of January 22, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA: - Patients with RRMS (2017 Mc Donald criteria) treated with highly active treatment in the first 5 years of symptoms onset, at least 1 year, with an EDSS below 4
  • HAT start after April 12th 2007 (availability of Natalizumab)
  • Naive or failure (or intolerability) to 1 or more first line DMT (injectables, teriflunomide, DMF).
  • * EDSS \< or equal 4 when starting HAT EXCLUSION CRITERIA:
  • Progressive relapsing MS at baseline
  • Clinical or basic MRI data unavailable after on-site visit.
  • MS diagnostic \> 5 years at baseline
  • Immunosuppressive drugs (Azathioprine, Cyclophosphamide, Mycophenolate, Methotrexate) prescribed before HAT initiation

About Centre Hospitalier Universitaire De Nice

The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.

Locations

Nice, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials